JP7328761B2 - 多価多重特異性ｏｘ４０結合融合タンパク質 - Google Patents

多価多重特異性ｏｘ４０結合融合タンパク質 Download PDF

Info

Publication number
JP7328761B2
JP7328761B2 JP2018535298A JP2018535298A JP7328761B2 JP 7328761 B2 JP7328761 B2 JP 7328761B2 JP 2018535298 A JP2018535298 A JP 2018535298A JP 2018535298 A JP2018535298 A JP 2018535298A JP 7328761 B2 JP7328761 B2 JP 7328761B2
Authority
JP
Japan
Prior art keywords
vhh
fusion protein
linker
binding
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018535298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504062A (ja
Inventor
ブレンダン ピー． エッケルマン
ジョン シー． ティマー
チェルシー ハタ
カイル エス． ジョーンズ
アブラヒム フセイン
アミール エス． ラザイ
ブライアン ベックランド
ラジェイ パンディット
マイク カプラン
ルーカス レイソン
クイン デヴロー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inhibrx Inc
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of JP2019504062A publication Critical patent/JP2019504062A/ja
Priority to JP2022154355A priority Critical patent/JP2022185021A/ja
Application granted granted Critical
Publication of JP7328761B2 publication Critical patent/JP7328761B2/ja
Priority to JP2025028636A priority patent/JP2025081649A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018535298A 2016-01-11 2017-01-11 多価多重特異性ｏｘ４０結合融合タンパク質 Active JP7328761B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022154355A JP2022185021A (ja) 2016-01-11 2022-09-28 多価多重特異性ｏｘ４０結合融合タンパク質
JP2025028636A JP2025081649A (ja) 2016-01-11 2025-02-26 多価多重特異性ｏｘ４０結合融合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662277027P 2016-01-11 2016-01-11
US62/277,027 2016-01-11
PCT/US2017/013070 WO2017123673A2 (en) 2016-01-11 2017-01-11 Multivalent and multispecific ox40-binding fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022154355A Division JP2022185021A (ja) 2016-01-11 2022-09-28 多価多重特異性ｏｘ４０結合融合タンパク質

Publications (2)

Publication Number Publication Date
JP2019504062A JP2019504062A (ja) 2019-02-14
JP7328761B2 true JP7328761B2 (ja) 2023-08-17

Family

ID=59275443

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018535298A Active JP7328761B2 (ja) 2016-01-11 2017-01-11 多価多重特異性ｏｘ４０結合融合タンパク質
JP2022154355A Pending JP2022185021A (ja) 2016-01-11 2022-09-28 多価多重特異性ｏｘ４０結合融合タンパク質
JP2025028636A Pending JP2025081649A (ja) 2016-01-11 2025-02-26 多価多重特異性ｏｘ４０結合融合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022154355A Pending JP2022185021A (ja) 2016-01-11 2022-09-28 多価多重特異性ｏｘ４０結合融合タンパク質
JP2025028636A Pending JP2025081649A (ja) 2016-01-11 2025-02-26 多価多重特異性ｏｘ４０結合融合タンパク質

Country Status (13)

Country Link
US (3) US20170198051A1 (enExample)
EP (1) EP3402507A4 (enExample)
JP (3) JP7328761B2 (enExample)
KR (1) KR20180098671A (enExample)
CN (1) CN108883153A (enExample)
AU (2) AU2017207318B2 (enExample)
BR (1) BR112018013911A2 (enExample)
CA (1) CA3009075A1 (enExample)
IL (2) IL298686A (enExample)
MX (2) MX2018008310A (enExample)
RU (1) RU2022106508A (enExample)
SG (1) SG11201805422WA (enExample)
WO (1) WO2017123673A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102410078B1 (ko) 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US20170198051A1 (en) 2016-01-11 2017-07-13 Inhibrx Lp Multivalent and multispecific ox40-binding fusion proteins
AU2017298483A1 (en) * 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric OX40 binding molecules and uses thereof
EP3494139B1 (en) * 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
UA127449C2 (uk) * 2016-09-23 2023-08-30 Мерус Н.В. Зв'язувальна молекула, яка модулює біологічну активність, що експресується клітиною
EA201991207A1 (ru) 2016-12-19 2019-12-30 Гленмарк Фармасьютикалс С.А. Новые агонисты tnfr и их применение
TW202515920A (zh) 2017-04-11 2025-04-16 美商因荷布瑞克斯生物科學公司 具有經受限cd3結合的多重特異性多肽構築體及使用其之方法
CA3059366A1 (en) 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
JP7362614B2 (ja) 2017-12-29 2023-10-17 エーピー バイオサイエンスィズ インコーポレイテッド 癌治療のために免疫チェックポイントを調節する単一特異性および二重特異性タンパク質
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
KR20210006913A (ko) 2018-04-11 2021-01-19 인히브릭스, 인크. 제한된 ｃｄ3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
CN112601761A (zh) 2018-08-13 2021-04-02 印希比股份有限公司 结合ox40的多肽及其用途
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3864049A1 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
CA3115082A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
US20210340273A1 (en) 2018-10-11 2021-11-04 Inhlbrx, inc. 5t4 single domain antibodies and therapeutic compositions thereof
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
CN113301919B (zh) * 2018-11-13 2025-01-28 Jn生物科学有限责任公司 激活免疫细胞的双特异性抗体
WO2020102647A1 (en) * 2018-11-15 2020-05-22 Invenra Inc. Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins
US12441783B2 (en) * 2019-01-07 2025-10-14 Bactolife Aps Pathogen binding proteins
TWI793395B (zh) * 2019-01-25 2023-02-21 大陸商信達生物製藥（蘇州）有限公司 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
CN114616247B (zh) * 2019-10-17 2024-06-28 江苏康宁杰瑞生物制药有限公司 Ox40/pd-l1双特异性抗体
WO2021084104A1 (en) * 2019-10-30 2021-05-06 Bioinvent International Ab Tetravalent antibody molecules
EP4077374A4 (en) * 2019-12-20 2023-12-27 Kisoji Biotechnology Inc. POLYPEPTIDES, PROTEIN COMPLEXES AND ASSOCIATED PRODUCTION PROCESS
CN115461371A (zh) * 2020-06-30 2022-12-09 和铂医药(上海)有限责任公司 靶向ox40的抗体及其制备方法和应用
EP3940931A1 (de) 2020-07-14 2022-01-19 Siemens Aktiengesellschaft Verfahren zur herstellung eines rotors einer asynchronmaschine
US20230303664A1 (en) * 2020-07-29 2023-09-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic and diagnostic vhh antibodies against sars-cov-2 and methods for their enhancement
WO2022243341A1 (en) * 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
WO2023089079A1 (en) * 2021-11-19 2023-05-25 Pieris Pharmaceuticals Gmbh Novel fusion protein specific for ox40 and pd-l1
JP2025501522A (ja) * 2021-12-17 2025-01-22 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
JP2025521865A (ja) * 2022-06-28 2025-07-10 ベイジン スターマブ バイオメド テクノロジ リミテッド 単特異性抗体および多重特異性抗体
CN118515763B (zh) * 2024-07-23 2024-11-01 北京百普赛斯生物科技股份有限公司 Il-6的抗体、检测试剂盒及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121810A2 (en) 2005-05-06 2006-11-16 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
JP2009504191A (ja) 2005-08-19 2009-02-05 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
JP2011024581A (ja) 2002-11-08 2011-02-10 Ablynx Nv 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
ATE430580T1 (de) * 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
JP5093097B2 (ja) 2006-03-03 2012-12-05 小野薬品工業株式会社 細胞表面機能分子の細胞外領域多量体
WO2007132461A2 (en) * 2006-05-11 2007-11-22 Ramot At Tel Aviv University Ltd. Classification of protein sequences and uses of classified proteins
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
BRPI1008692B8 (pt) 2009-02-17 2021-05-25 Ucb Biopharma Sprl anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
EP3309176B1 (en) * 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
EP2550529B1 (en) * 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
JP5997154B2 (ja) 2010-08-16 2016-09-28 ノビミューン エスアー 多重特異性多価抗体の生成方法
PH12014500089A1 (en) * 2011-07-11 2014-02-17 Ichnos Sciences SA Antibodies that bind to ox40 and their uses
EA028183B1 (ru) * 2012-02-27 2017-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Cx3cr1-связывающие полипептиды
AU2013256802A1 (en) 2012-04-30 2014-12-11 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
WO2014022592A1 (en) * 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
JP2016514676A (ja) * 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
MD20180107A2 (ro) 2013-03-18 2019-06-30 Biocerox Products B.V. Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
SG10201807625PA (en) * 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US20170198051A1 (en) * 2016-01-11 2017-07-13 Inhibrx Lp Multivalent and multispecific ox40-binding fusion proteins
EA201991207A1 (ru) * 2016-12-19 2019-12-30 Гленмарк Фармасьютикалс С.А. Новые агонисты tnfr и их применение

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011024581A (ja) 2002-11-08 2011-02-10 Ablynx Nv 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
WO2006121810A2 (en) 2005-05-06 2006-11-16 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
JP2009504191A (ja) 2005-08-19 2009-02-05 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｔｒｅｎｄｓ ｉｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ，２０１０，Ｖｏｌ．２８，ｐｐ．３５２－３６２

Also Published As

Publication number Publication date
MX2024004017A (es) 2024-05-08
US20220106397A1 (en) 2022-04-07
JP2022185021A (ja) 2022-12-13
US11117972B2 (en) 2021-09-14
NZ743731A (en) 2025-06-27
RU2018128629A3 (enExample) 2020-06-16
RU2018128629A (ru) 2020-02-13
IL298686A (en) 2023-01-01
BR112018013911A2 (pt) 2018-12-18
EP3402507A4 (en) 2019-08-07
WO2017123673A2 (en) 2017-07-20
SG11201805422WA (en) 2018-07-30
IL260531B1 (en) 2023-01-01
AU2017207318A1 (en) 2018-07-12
CN108883153A (zh) 2018-11-23
US20170198051A1 (en) 2017-07-13
EP3402507A2 (en) 2018-11-21
AU2024200551A1 (en) 2024-02-22
RU2022106508A (ru) 2022-04-05
AU2017207318B2 (en) 2023-12-07
IL260531A (enExample) 2018-08-30
IL260531B2 (en) 2023-05-01
MX2018008310A (es) 2019-01-28
JP2025081649A (ja) 2025-05-27
KR20180098671A (ko) 2018-09-04
CA3009075A1 (en) 2017-07-20
JP2019504062A (ja) 2019-02-14
US12227584B2 (en) 2025-02-18
US20190263916A1 (en) 2019-08-29
WO2017123673A3 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
JP7328761B2 (ja) 多価多重特異性ｏｘ４０結合融合タンパク質
JP7510447B2 (ja) Ｐｄ－ｌ１－結合融合タンパク質
JP2025081307A (ja) Ｎｋ細胞結合抗体融合構築物
KR20230084507A (ko) 다중-특이적 면역 표적화 분자 및 그의 용도
EP3288974B1 (en) Type iii secretion system targeting molecules
US20250122299A1 (en) ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES
CN115175936B (zh) 用于治疗实体瘤的靶向间皮素的cd40激动性多特异性抗体构建体
RU2773052C2 (ru) Поливалентные и полиспецифические ох40-связывающие слитые белки
RU2789648C2 (ru) Мультивалентные и мультиспецифические 41bb-связывающие слитые белки
RU2779489C2 (ru) Антитела, связывающие cd3
HK1250991B (en) Type iii secretion system targeting molecules

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211223

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220531

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220928

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20221011

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221011

C876 Explanation why request for accelerated appeal examination is justified

Free format text: JAPANESE INTERMEDIATE CODE: C876

Effective date: 20221110

C305 Report on accelerated appeal examination

Free format text: JAPANESE INTERMEDIATE CODE: C305

Effective date: 20221115

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221122

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230309

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230804

R150 Certificate of patent or registration of utility model

Ref document number: 7328761

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350